What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens”In the company’s words, NCT05885464 on ClinicalTrials.gov
- Tested for
- Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
- Main trialPhase 1/2
- “This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.”In the company’s words, NCT05885464 on ClinicalTrials.gov
Other drugs for Lymphoblastic Lymphoma
- TisagenlecleucelNovartis · Phase 3
- VenetoclaxAbbVie · Phase 3
- RemimazolamAcacia Pharma Ltd · Phase 2/3
- BlinatumomabAmgen · Phase 3
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Orca-TOrca Biosystems, Inc. · Phase 3
Coming up1
- DecPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Dec 2026 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026